THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) and Pfizer Inc. (PFE) announced results of the second and final period of the PRESERVE trial. PRESERVE is a two-period multi-center trial in patients with moderately active rheumatoid arthritis who achieved Disease Activity Score 28 low disease activity or clinical remission on combination Enbrel plus methotrexate in Period one and were randomized to continue on ENBREL plus MTX or MTX alone in Period two.
Results of Period two showed that the percentage of patients who maintained LDA or achieved clinical remission at week 88 was significantly higher in patients receiving ENBREL plus MTX than those on MTX alone.
The PRESERVE trial met both its primary and conditional primary endpoints by demonstrating a statistically superior response in moderately active RA patients taking ENBREL 50mg weekly plus MTX or ENBREL 25mg QW plus MTX compared with those taking MTX monotherapy at 88 weeks.
Copyright RTT News/dpa-AFX